查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2046826

血液腫瘤檢測市場－全球產業規模、佔有率、趨勢、機會和預測：按癌症類型、產品、技術、地區和競爭格局分類，2021-2031年

Hemato Oncology Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer Type, By Product, By Technology By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球血液惡性腫瘤檢測市場預計將大幅擴張，從 2025 年的 32.1 億美元成長到 2031 年的 53.7 億美元，複合年成長率達到 8.95%。

該市場主要由用於識別、預測和後續觀察骨髓惡性腫瘤（例如白血病、淋巴瘤和多發性骨髓瘤）的診斷程序和檢測組成。其主要成長要素並非人工智慧等新興市場趨勢，而是全球血液系統癌症發生率的不斷上升以及易患這些疾病的人口老化。例如，美國癌症協會估計，到2025年，美國白血病、淋巴瘤和多發性骨髓瘤的診斷總合將達到192,070例。儘管需求強勁，但主要障礙包括先進基因組檢測設備所需的高額資本投入以及複雜的報銷政策，這些都限制了許多醫療保健系統獲得必要的診斷服務。

市場概覽
預測期 2027-2031
市場規模：2025年 32.1億美元
市場規模：2031年 53.7億美元
複合年成長率：2026-2031年 8.95%
成長最快的細分市場 白血病
最大的市場 北美洲

市場促進因素

市場成長主要得益於次世代定序(NGS) 和分子診斷技術的進步，這些技術正在從根本上改變骨髓惡性腫瘤的臨床管理。這些技術能夠精準識別基因突變和染色體異常，例如 BCR-ABL 和 FLT3，這對於診斷和標靶治療的選擇至關重要。精準腫瘤學的興起正在加速高通量定序技術能夠提供更快的結果和更高的靈敏度。這種技術發展動能也體現在像 Tempus AI 這樣的創新公司的財務表現上。該公司報告稱，2025 年第二季基因組學相關銷售額達到 2.418 億美元，年成長 115.3%，主要得益於腫瘤檢測需求的成長。此外，骨髓惡性腫瘤的發生率不斷上升，根據英國血液癌症協會（Blood Cancer UK）2025年2月報告，英國約有28萬人患有血液癌症，這迫切需要進行廣泛的檢測以進行早期發現和疾病監測。如此龐大的患者群體保證了對初始診斷檢測和常規微量殘存疾病（MPD）檢測的持續需求，而像Illumina這樣的大型診斷公司也為此提供了支持。 Illumina在2024年累計的銷售額高達43億美元。這充分展現了基因組檢測基礎設施龐大的商業性規模。

市場挑戰

全球血液系統惡性腫瘤檢測市場擴張的一大障礙是先進基因組檢測設備所需的大量資金投入。檢查室和醫療機構在部署這些複雜的診斷平台時面臨著巨大的經濟負擔，而這些平台還需要大量的配套基礎設施和專業的維護。這種高進入門檻限制了基因組分析能力的應用，使其主要局限於資金雄厚的學術機構和大規模參考實驗室，而小規模地方醫院和診所則被排除在外。因此，預算緊張的醫療機構儘管擁有重要的臨床價值，卻無力投資這項關鍵技術，造成了設備採購的瓶頸。這種資金限制直接限制了特定地區的檢測數量，迫使醫療機構將檢體外包，並經常導致物流延誤。這種設備普及率低與骨髓惡性腫瘤的嚴重性所帶來的迫切臨床需求形成了鮮明對比。美國癌症協會預測，到 2025 年，美國將有 56110 人死於白血病、淋巴瘤和多發性骨髓瘤，凸顯了普及檢測的迫切需要，而目前高昂的設備成本阻礙了這一需求。

市場趨勢

由於用於微量殘存疾病（MRD）監測的液態生物檢體的快速普及，骨髓惡性腫瘤治療後的後續觀察方式正在迅速改變。這一趨勢標誌著從侵入性骨髓穿刺到高靈敏度周邊血液檢測的根本性轉變，從而能夠頻繁、即時地追蹤白血病克隆（白血病細胞群）。臨床醫生擴大利用這些非侵入性檢測方法，比傳統方法更早發現無症狀性復發，從而實現及時的治療性介入。 Adaptive Biotechnologies 公司的業績證明了這種方法的商業性成功。該公司報告稱，其 MRD 相關銷售額在 2024 年第三季達到 3,750 萬美元，年增 52%，這主要得益於其用於淋巴瘤的 clonoSEQ 檢測方法的廣泛應用。同時，市場正在進行策略整合，以拓展分子診斷產品組合。領先的參考實驗室正積極收購專業的基因組學相關資產，以建造全面的「一站式」腫瘤檢測中心。這項策略將使主要供應商能夠將專有基因panel和EXOME序等小眾且高度複雜的檢測整合到其現有的服務基礎設施中，從而擴大其在診斷工作流程中的市場佔有率。一個值得關注的例子是Labcorp於2024年4月達成協議，收購Invitae的部分檢測資產。預計此交易每年將帶來約2.75億至3億美元的收入，並顯著提升公司在癌症和罕見疾病診斷方面的能力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球血液腫瘤檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 癌症類型（白血病、淋巴瘤、骨髓增生性腫瘤、其他癌症）
    • 產品類別（暗殺工具包和試劑、服務）
    • 依技術（PCR、IHC、NGS、細胞遺傳學等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美血液腫瘤檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲血液腫瘤檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區血液腫瘤檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲血液腫瘤檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲血液腫瘤檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球血液腫瘤檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F. Hoffmann-La Roche Ltd
  • EntroGen, Inc.
  • Qiagen NV
  • Abbott Laboratories Inc.
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • Amoy Diagnostics Co. Ltd.
  • ASURAGEN, INC
  • ArcherDX, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 21649

The Global Hemato Oncology Testing Market is set for significant expansion, projected to grow from USD 3.21 Billion in 2025 to USD 5.37 Billion by 2031, achieving an 8.95% CAGR. This market centers on diagnostic procedures and assays used for identifying, predicting the course of, and monitoring hematologic malignancies, including leukemia, lymphoma, and myeloma. The primary drivers are the increasing global incidence of blood cancers and an aging population more susceptible to these conditions, distinct from evolving market trends like AI integration. For instance, the American Cancer Society estimated 192,070 combined diagnoses of leukemia, lymphoma, or myeloma in the U.S. in 2025. Despite this strong demand, a key obstacle is the high capital expenditure for advanced genomic testing instruments and complex reimbursement policies, which limit access to vital diagnostic services across many healthcare systems.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.21 Billion
Market Size 2031USD 5.37 Billion
CAGR 2026-20318.95%
Fastest Growing SegmentLeukemia
Largest MarketNorth America

Market Driver

Market growth is primarily propelled by advancements in Next-Generation Sequencing (NGS) and molecular diagnostics, which are fundamentally transforming the clinical management of hematologic malignancies. These technologies enable precise identification of genetic mutations and chromosomal abnormalities, such as BCR-ABL or FLT3, crucial for diagnosis and selecting targeted therapies. The move towards precision oncology has accelerated the adoption of high-throughput sequencing panels, offering faster results and higher sensitivity than traditional cytogenetics. This technological momentum is evident in the financial performance of innovators like Tempus AI, which reported a 115.3% year-over-year increase in genomics revenue to $241.8 million in Q2 2025, driven by rising oncology testing volumes. Additionally, the escalating prevalence of hematologic malignancies, like the approximately 280,000 individuals living with blood cancer in the UK as reported by Blood Cancer UK in February 2025, necessitates widespread testing for early detection and disease monitoring. This substantial patient pool ensures sustained demand for initial diagnostic workups and recurring minimal residual disease testing, supported by major diagnostic corporations like Illumina, which generated $4.3 billion in fiscal year revenue for 2024, highlighting the vast commercial scale of the genomic testing infrastructure.

Market Challenge

A significant impediment to the expansion of the Global Hemato Oncology Testing Market is the substantial capital expenditure required for advanced genomic testing instruments. Laboratories and healthcare institutions face considerable financial burdens in acquiring these complex diagnostic platforms, which also demand extensive infrastructure and specialized maintenance. This high entry barrier restricts the adoption of genomic profiling capabilities mainly to well-funded academic centers and large reference laboratories, thereby excluding smaller regional hospitals and community clinics. Consequently, a bottleneck in equipment procurement arises, as budget-constrained facilities are unable to invest in this crucial technology despite its clinical value. This financial constraint directly limits local testing volumes, often forcing healthcare providers to outsource samples and introducing logistical delays. The inability to widely deploy these instruments stands in stark contrast to the urgent clinical demand driven by the severity of hematologic malignancies; the American Cancer Society projected 56,110 U.S. deaths from leukemia, lymphoma, and myeloma in 2025, underscoring the critical need for accessible testing currently hindered by prohibitive equipment costs.

Market Trends

The post-treatment surveillance landscape for hematologic malignancies is rapidly being transformed by the accelerated adoption of liquid biopsy for Minimal Residual Disease (MRD) monitoring. This trend signifies a fundamental shift from invasive bone marrow aspirates to highly sensitive, peripheral blood-based testing, allowing for frequent, real-time tracking of leukemic clones. Clinicians are increasingly utilizing these non-invasive assays to detect sub-clinical relapse earlier than standard methods, facilitating timely therapeutic interventions. The commercial success of this approach is demonstrated by Adaptive Biotechnologies, which reported a 52% year-over-year growth in MRD revenue to $37.5 million in Q3 2024, driven by the expanding use of its clonoSEQ assay for lymphoid cancers. Concurrently, the market is experiencing strategic consolidation to broaden molecular diagnostic portfolios, with major reference laboratories actively acquiring specialized genomic assets to create comprehensive "one-stop" oncology testing hubs. This strategy allows large providers to integrate niche, high-complexity assays, such as proprietary genetic panels and exome sequencing, into their existing service infrastructure, thus capturing a larger share of the diagnostic workflow. A notable example is Labcorp's April 2024 agreement to acquire select testing assets from Invitae, a transaction expected to generate approximately $275 million to $300 million in annual revenue, significantly enhancing its capabilities in oncology and rare disease diagnostics.

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • EntroGen, Inc.
  • Qiagen N.V.
  • Abbott Laboratories Inc.
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • Amoy Diagnostics Co. Ltd.
  • ASURAGEN, INC
  • ArcherDX, Inc

Report Scope

In this report, the Global Hemato Oncology Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hemato Oncology Testing Market, By Cancer Type

  • Leukemia
  • Lymphoma
  • Myeloproliferative Neoplasms
  • Other Cancers

Hemato Oncology Testing Market, By Product

  • Assay Kits and Reagents
  • Services

Hemato Oncology Testing Market, By Technology

  • PCR
  • IHC
  • NGS
  • Cytogenetics
  • Other

Hemato Oncology Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hemato Oncology Testing Market.

Available Customizations:

Global Hemato Oncology Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hemato Oncology Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Cancer Type (Leukemia, Lymphoma, Myeloproliferative Neoplasms, Other Cancers)
    • 5.2.2. By Product (Assay Kits and Reagents, Services)
    • 5.2.3. By Technology (PCR, IHC, NGS, Cytogenetics, Other)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Hemato Oncology Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Cancer Type
    • 6.2.2. By Product
    • 6.2.3. By Technology
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Hemato Oncology Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Cancer Type
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Technology
    • 6.3.2. Canada Hemato Oncology Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Cancer Type
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Technology
    • 6.3.3. Mexico Hemato Oncology Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Cancer Type
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Technology

7. Europe Hemato Oncology Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Cancer Type
    • 7.2.2. By Product
    • 7.2.3. By Technology
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Hemato Oncology Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Cancer Type
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Technology
    • 7.3.2. France Hemato Oncology Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Cancer Type
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Technology
    • 7.3.3. United Kingdom Hemato Oncology Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Cancer Type
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Technology
    • 7.3.4. Italy Hemato Oncology Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Cancer Type
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Technology
    • 7.3.5. Spain Hemato Oncology Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Cancer Type
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Technology

8. Asia Pacific Hemato Oncology Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Cancer Type
    • 8.2.2. By Product
    • 8.2.3. By Technology
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Hemato Oncology Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Cancer Type
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Technology
    • 8.3.2. India Hemato Oncology Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Cancer Type
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Technology
    • 8.3.3. Japan Hemato Oncology Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Cancer Type
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Technology
    • 8.3.4. South Korea Hemato Oncology Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Cancer Type
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Technology
    • 8.3.5. Australia Hemato Oncology Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Cancer Type
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Technology

9. Middle East & Africa Hemato Oncology Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Cancer Type
    • 9.2.2. By Product
    • 9.2.3. By Technology
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Hemato Oncology Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Cancer Type
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Technology
    • 9.3.2. UAE Hemato Oncology Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Cancer Type
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Technology
    • 9.3.3. South Africa Hemato Oncology Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Cancer Type
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Technology

10. South America Hemato Oncology Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Cancer Type
    • 10.2.2. By Product
    • 10.2.3. By Technology
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Hemato Oncology Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Cancer Type
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Technology
    • 10.3.2. Colombia Hemato Oncology Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Cancer Type
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Technology
    • 10.3.3. Argentina Hemato Oncology Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Cancer Type
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Hemato Oncology Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. EntroGen, Inc.
  • 15.3. Qiagen N.V.
  • 15.4. Abbott Laboratories Inc.
  • 15.5. Thermo Fisher Scientific, Inc.
  • 15.6. Bio-Rad Laboratories, Inc.
  • 15.7. Illumina, Inc.
  • 15.8. Amoy Diagnostics Co. Ltd.
  • 15.9. ASURAGEN, INC
  • 15.10. ArcherDX, Inc

16. Strategic Recommendations

17. About Us & Disclaimer